Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Syncope in Brugada syndrome patients: prevalence, characteristics, and outcome.

Sacher F, Arsac F, Wilton SB, Derval N, Denis A, de Guillebon M, Ramoul K, Bordachar P, Ritter P, Hocini M, Clémenty J, Jaïs P, Haïssaguerre M.

Heart Rhythm. 2012 Aug;9(8):1272-9. doi: 10.1016/j.hrthm.2012.04.013. Epub 2012 Apr 10.

PMID:
22504046
2.

Clinical characteristics and treatment outcomes of patients with Brugada syndrome in northeastern Thailand.

Makarawate P, Chaosuwannakit N, Vannaprasaht S, Tassaneeyakul W, Sawanyawisuth K.

Singapore Med J. 2014 Apr;55(4):217-20.

3.

Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience.

Conte G, Sieira J, Ciconte G, de Asmundis C, Chierchia GB, Baltogiannis G, Di Giovanni G, La Meir M, Wellens F, Czapla J, Wauters K, Levinstein M, Saitoh Y, Irfan G, Julià J, Pappaert G, Brugada P.

J Am Coll Cardiol. 2015 Mar 10;65(9):879-88. doi: 10.1016/j.jacc.2014.12.031.

4.

Low disease prevalence and inappropriate implantable cardioverter defibrillator shock rate in Brugada syndrome: a nationwide study.

Holst AG, Jensen HK, Eschen O, Henriksen FL, Kanters J, Bundgaard H, Svendsen JH, Haunsø S, Tfelt-Hansen J.

Europace. 2012 Jul;14(7):1025-9. doi: 10.1093/europace/eus002. Epub 2012 Jan 27.

PMID:
22286273
5.

Use of implantable loop recorders in patients with Brugada syndrome and suspected risk of ventricular arrhythmia.

Kubala M, Aïssou L, Traullé S, Gugenheim AL, Hermida JS.

Europace. 2012 Jun;14(6):898-902. doi: 10.1093/europace/eur319. Epub 2011 Oct 6.

PMID:
21979995
6.

Syncope in Brugada syndrome: prevalence, clinical significance, and clues from history taking to distinguish arrhythmic from nonarrhythmic causes.

Olde Nordkamp LR, Vink AS, Wilde AA, de Lange FJ, de Jong JS, Wieling W, van Dijk N, Tan HL.

Heart Rhythm. 2015 Feb;12(2):367-75. doi: 10.1016/j.hrthm.2014.10.014. Epub 2014 Oct 13.

PMID:
25311410
7.

Long-term prognosis of patients with Brugada syndrome and an implanted cardioverter-defibrillator.

Dores H, Reis Santos K, Adragão P, Moscoso Costa F, Galvão Santos P, Carmo P, Cavaco D, Bello Morgado F, Mendes M.

Rev Port Cardiol. 2015 Jun;34(6):395-402. doi: 10.1016/j.repc.2014.12.006. Epub 2015 May 29.

PMID:
26028488
8.

Long-term follow-up of asymptomatic Brugada patients with inducible ventricular fibrillation under hydroquinidine.

Bouzeman A, Traulle S, Messali A, Extramiana F, Denjoy I, Narayanan K, Marijon E, Hermida JS, Leenhardt A.

Europace. 2014 Apr;16(4):572-7. doi: 10.1093/europace/eut279. Epub 2013 Sep 25.

PMID:
24068450
9.

Evaluation of the necessity for cardioverter-defibrillator implantation in elderly patients with Brugada syndrome.

Kamakura T, Wada M, Nakajima I, Ishibashi K, Miyamoto K, Okamura H, Noda T, Aiba T, Takaki H, Yasuda S, Ogawa H, Shimizu W, Makiyama T, Kimura T, Kamakura S, Kusano K.

Circ Arrhythm Electrophysiol. 2015 Aug;8(4):785-91. doi: 10.1161/CIRCEP.114.002705. Epub 2015 Jun 11.

10.

Outcome after implantation of cardioverter defibrillator [corrected] in patients with Brugada syndrome: a multicenter Israeli study (ISRABRU).

Rosso R, Glick A, Glikson M, Wagshal A, Swissa M, Rosenhek S, Shetboun I, Khalamizer V, Fuchs T, Boulos M, Geist M, Strasberg B, Ilan M, Belhassen B; Israeli Working Group on Cardiac Pacing and Electrophysiology.

Isr Med Assoc J. 2008 Jun;10(6):435-9. Erratum in: Isr Med Assoc J. 2008 Jul;10(7):549.

11.

Long-term prognosis in patients with Brugada syndrome based on Class II indication for implantable cardioverter-defibrillator in the HRS/EHRA/APHRS Expert Consensus Statement: multicenter study in Japan.

Takagi M, Sekiguchi Y, Yokoyama Y, Aihara N, Hiraoka M, Aonuma K; Japan Idiopathic Ventricular Fibrillation Study (J-IVFS) Investigators.

Heart Rhythm. 2014 Oct;11(10):1716-20. doi: 10.1016/j.hrthm.2014.06.033. Epub 2014 Jun 27.

PMID:
24981871
12.

Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study-part 2.

Sacher F, Probst V, Maury P, Babuty D, Mansourati J, Komatsu Y, Marquie C, Rosa A, Diallo A, Cassagneau R, Loizeau C, Martins R, Field ME, Derval N, Miyazaki S, Denis A, Nogami A, Ritter P, Gourraud JB, Ploux S, Rollin A, Zemmoura A, Lamaison D, Bordachar P, Pierre B, Jaïs P, Pasquié JL, Hocini M, Legal F, Defaye P, Boveda S, Iesaka Y, Mabo P, Haïssaguerre M.

Circulation. 2013 Oct 15;128(16):1739-47. doi: 10.1161/CIRCULATIONAHA.113.001941. Epub 2013 Aug 30.

13.

Hydroquinidine therapy in Brugada syndrome.

Hermida JS, Denjoy I, Clerc J, Extramiana F, Jarry G, Milliez P, Guicheney P, Di Fusco S, Rey JL, Cauchemez B, Leenhardt A.

J Am Coll Cardiol. 2004 May 19;43(10):1853-60.

14.

Risk stratification in patients with Brugada syndrome without previous cardiac arrest – prognostic value of combined risk factors.

Okamura H, Kamakura T, Morita H, Tokioka K, Nakajima I, Wada M, Ishibashi K, Miyamoto K, Noda T, Aiba T, Nishii N, Nagase S, Shimizu W, Yasuda S, Ogawa H, Kamakura S, Ito H, Ohe T, Kusano KF.

Circ J. 2015;79(2):310-7. doi: 10.1253/circj.CJ-14-1059. Epub 2014 Nov 26.

15.

Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study.

Sacher F, Probst V, Iesaka Y, Jacon P, Laborderie J, Mizon-Gérard F, Mabo P, Reuter S, Lamaison D, Takahashi Y, O'Neill MD, Garrigue S, Pierre B, Jaïs P, Pasquié JL, Hocini M, Salvador-Mazenq M, Nogami A, Amiel A, Defaye P, Bordachar P, Boveda S, Maury P, Klug D, Babuty D, Haïssaguerre M, Mansourati J, Clémenty J, Le Marec H.

Circulation. 2006 Nov 28;114(22):2317-24. Epub 2006 Nov 20.

16.

Risk stratification in individuals with the Brugada type 1 ECG pattern without previous cardiac arrest: usefulness of a combined clinical and electrophysiologic approach.

Delise P, Allocca G, Marras E, Giustetto C, Gaita F, Sciarra L, Calo L, Proclemer A, Marziali M, Rebellato L, Berton G, Coro L, Sitta N.

Eur Heart J. 2011 Jan;32(2):169-76. doi: 10.1093/eurheartj/ehq381. Epub 2010 Oct 26.

17.

Management of Brugada Syndrome: Thirty-Three-Year Experience Using Electrophysiologically Guided Therapy With Class 1A Antiarrhythmic Drugs.

Belhassen B, Rahkovich M, Michowitz Y, Glick A, Viskin S.

Circ Arrhythm Electrophysiol. 2015 Dec;8(6):1393-402. doi: 10.1161/CIRCEP.115.003109. Epub 2015 Sep 9.

18.

Prognosis after implantation of cardioverter-defibrillators in Korean patients with Brugada syndrome.

Son MK, Byeon K, Park SJ, Kim JS, Nam GB, Choi KJ, Kim YH, Park SW, Kim YH, Park HW, Cho JG, On YK.

Yonsei Med J. 2014 Jan;55(1):37-45. doi: 10.3349/ymj.2014.55.1.37.

19.

The Brugada syndrome in Canada: a unique French-Canadian experience.

Champagne J, Philippon F, Gilbert M, Molin F, Blier L, Nault I, Sarrazin JF, Charbonneau L, Dufort L, Drolet B, Chahine M, O'Hara GE.

Can J Cardiol. 2007 Oct;23 Suppl B:71B-75B. Erratum in: Can J Cardiol. 2009 Mar;25(3):140.

20.

Prevalence of type 1 Brugada ECG pattern after administration of Class 1C drugs in patients with type 1 myotonic dystrophy: Myotonic dystrophy as a part of the Brugada syndrome.

Maury P, Audoubert M, Cintas P, Rollin A, Duparc A, Mondoly P, Chiriac AM, Acket B, Zhao X, Pasquié JL, Cardin C, Delay M, Sadron M, Carrié D, Galinier M, Davy JM, Arne-Bès MC, Raczka F.

Heart Rhythm. 2014 Oct;11(10):1721-7. doi: 10.1016/j.hrthm.2014.07.011. Epub 2014 Jul 9.

PMID:
25016148

Supplemental Content

Support Center